TY  - JOUR
AU  - Janssens, Geert O
AU  - Gandola, Lorenza
AU  - Bolle, Stephanie
AU  - Mandeville, Henry
AU  - Ramos-Albiac, Monica
AU  - van Beek, Karen
AU  - Benghiat, Helen
AU  - Hoeben, Bianca
AU  - Morales La Madrid, Andres
AU  - Kortmann, Rolf-Dieter
AU  - Hargrave, Darren
AU  - Menten, Johan
AU  - Pecori, Emilia
AU  - Biassoni, Veronica
AU  - von Bueren, Andre O
AU  - van Vuurden, Dannis G
AU  - Massimino, Maura
AU  - Sturm, Dominik
AU  - Peters, Max
AU  - Kramm, Christof M
TI  - Survival benefit for patients with diffuse intrinsic pontine glioma (DIPG) undergoing re-irradiation at first progression: A matched-cohort analysis on behalf of the SIOP-E-HGG/DIPG working group.
JO  - European journal of cancer
VL  - 73
SN  - 0959-8049
CY  - Amsterdam [u.a.]
PB  - Elsevier
M1  - DKFZ-2017-00925
SP  - 38 - 47
PY  - 2017
AB  - Overall survival (OS) of patients with diffuse intrinsic pontine glioma (DIPG) is poor. The purpose of this study is to analyse benefit and toxicity of re-irradiation at first progression.At first progression, 31 children with DIPG, aged 2-16 years, underwent re-irradiation (dose 19.8-30.0 Gy) alone (n = 16) or combined with systemic therapy (n = 15). At initial presentation, all patients had typical symptoms and characteristic MRI features of DIPG, or biopsy-proven high-grade glioma. An interval of ≥3 months after upfront radiotherapy was required before re-irradiation. Thirty-nine patients fulfilling the same criteria receiving radiotherapy at diagnosis, followed by best supportive care (n = 20) or systemic therapy (n = 19) at progression but no re-irradiation, were eligible for a matched-cohort analysis.Median OS for patients undergoing re-irradiation was 13.7 months. For a similar median progression-free survival after upfront radiotherapy (8.2 versus 7.7 months; P = .58), a significant benefit in median OS (13.7 versus 10.3 months; P = .04) was observed in favour of patients undergoing re-irradiation. Survival benefit of re-irradiation increased with a longer interval between end-of-radiotherapy and first progression (3-6 months: 4.0 versus 2.7; P < .01; 6-12 months: 6.4 versus 3.3; P = .04). Clinical improvement with re-irradiation was observed in 24/31 (77
LB  - PUB:(DE-HGF)16
C6  - pmid:28161497
DO  - DOI:10.1016/j.ejca.2016.12.007
UR  - https://inrepo02.dkfz.de/record/120496
ER  -